Skip to content

Anxiety: all studies

Page 291 of 772: studies 2,901 to 2,910 of 7,715, newest first. Back to the anxiety overview

Research

Mindfulness-based stress reduction for the treatment of adolescent psychiatric outpatients: A randomized clinical trial.

Journal of Consulting and Clinical Psychology 2009 Gina M. Biegel, Kirk Warren Brown, Shauna L. Shapiro et al. 657 citations

Research has shown that mindfulness-based treatment interventions may be effective for a range of mental and physical health disorders in adult populations, but little is known about the effectiveness of such interventions for treating adolescent conditions. The present randomized clinical trial was designed to assess the effect of the mindfulness-based stress reduction (MBSR) program for...

DOI: 10.1037/a0016241 (opens in new tab) Anxiety Randomized controlled trial Psychological intervention Mindfulness-based stress reduction +4

Distinct Effects of Δ9-Tetrahydrocannabinol and Cannabidiol on Neural Activation During Emotional Processing

Archives of General Psychiatry 2009 Paolo Fusar‐poli, José A. Crippa, Sagnik Bhattacharyya et al. 461 citations

CONTEXT: Cannabis use can both increase and reduce anxiety in humans. The neurophysiological substrates of these effects are unknown. OBJECTIVE: To investigate the effects of 2 main psychoactive constituents of Cannabis sativa (Delta9-tetrahydrocannabinol [Delta9-THC] and cannabidiol [CBD]) on regional brain function during emotional processing. DESIGN: Subjects were studied on 3 separate...

Mindfulness-based cognitive therapy: Further issues in current evidence and future research.

Journal of Consulting and Clinical Psychology June 1, 2008 J. Mark G. Williams, Ian Russell, Daphne Russell 165 citations

The authors respond to the article by H. F. Coelho, P. H. Canter, and E. Ernst (2007), which reviewed the current status of mindfulness-based cognitive therapy (MBCT). First, they clarify the randomization procedures in the 2 main MBCT trials. Second, they report posttreatment and follow-up data to show that trial participants allocated to "treatment as usual" did not become worse. Third, they...

DOI: 10.1037/0022-006x.76.3.524 (opens in new tab) Anxiety Mindfulness-based cognitive therapy Psychotherapist Beck depression inventory +4

Sleep paralysis and trauma, psychiatric symptoms and disorders in an adult African American population attending primary medical care.

Depression and Anxiety 2008 Thomas A. Mellman, Notalelomwan Aigbogun, Ruth Elaine Graves et al.

The occurrence of sleep paralysis (SP) absent narcolepsy appears to not be uncommon in African Americans and probably other non-European groups. Prior research has linked SP to trauma and psychiatric disorders and suggested a specific relationship to panic disorder in African Americans. The objective of our study was to evaluate relationships of SP with trauma, concurrent psychiatric symptoms...

Between Prohibitions: Patterns and Meanings of Magic Mushroom Use in the UK

Substance Use & Misuse 2008 Sarah Riley, Graham Blackman 36 citations

A survey of magic mushroom use was completed by 174 participants in 2004, a year when the sale of hallucinogenic mushrooms was not illegal in the UK. The data were collected in Edinburgh and Bristol (UK). Participants were a self-selecting convenience sample. Participants tended to be in their 20s, White-British, in education or employed; 64% were male. Participants reported a pattern of...

DOI: 10.1080/10826080701772363 (opens in new tab) Anxiety Feeling Paranoia Harm reduction +1

Depressive symptomatology in young adults with a history of MDMA use: a longitudinal analysis

Journal of Psychopharmacology August 22, 2007 Rüssel S. Falck, Jichuan Wang, Robert G. Carlson 45 citations

Research suggests that methylenedioxymethamphetamine (MDMA)/`ecstasy' can cause serotonin depletion as well as serotonergic neurodegradation that may result in depression. This longitudinal study used the Beck Depression Inventory (BDI-II) to assess depressive symptomatology every six months over a two-year period among a community sample of young adult MDMA/`ecstasy' users ( n = 402)....

The psychological and neurophysiological concomitants of mindfulness forms of meditation

Acta Neuropsychiatrica April 1, 2007 Belinda Ivanovski, Gin S. Malhi 282 citations

OBJECTIVE: To provide a comprehensive review and evaluation of the psychological and neurophysiological literature pertaining to mindfulness meditation. METHODS: A search for papers in English was undertaken using PsycINFO (from 1804 onward), MedLine (from 1966 onward) and the Cochrane Library with the following search terms: Vipassana, Mindfulness, Meditation, Zen, Insight, EEG, ERP, fMRI,...

Single Versus Repeated Sessions of Ketamine-Assisted Psychotherapy for People with Heroin Dependence

Journal of Psychoactive Drugs March 1, 2007 Evgeny Krupitsky, Andrei M. Burakov, Igor Dunaevsky et al. 176 citations

A prior study found that one ketamine-assisted psychotherapy session was significantly more effective than active placebo in promoting abstinence (Krupitsky et al. 2002). In this study of the efficacy of single versus repeated sessions of ketamine-assisted psychotherapy in promoting abstinence in people with heroin dependence, 59 detoxified inpatients with heroin dependence received a...

Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder

The Journal of Clinical Psychiatry November 15, 2006 Francisco Moreno, Christopher B. Wiegand, E. Keolani Taitano et al. 786 citations

In a controlled clinical environment, psilocybin was safely used in subjects with OCD and was associated with acute reductions in core OCD symptoms in several subjects.

MDMA in Adolescent Male Rats

Annals of the New York Academy of Sciences August 1, 2006 Raquel Faria, Ana Magalhães, Pedro Monteiro et al. 29 citations

Abstract: Long‐term behavioral consequences of the neurotoxicity produced by 3,4‐methylenedioxymethamphetamine (MDMA) in the adolescent rat are still mostly unknown. Here, adolescent male rats (postnatal day 45 PND [45]) were exposed to 10 mg/kg of MDMA, intraperitoneally, every 2 h for 6 h. Controls were given 0.9% saline in the same protocol. Ten days after exposure, the behavioral effects of...